Becton, Dickinson and Company (NYSE:BDX - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Investors acquired 66,192 put options on the stock. This is an increase of approximately 1,734% compared to the typical daily volume of 3,609 put options.
Becton, Dickinson and Company Stock Up 0.9%
BDX traded up $1.59 on Thursday, reaching $174.31. The company's stock had a trading volume of 1,664,312 shares, compared to its average volume of 1,962,907. The company has a market capitalization of $49.96 billion, a price-to-earnings ratio of 28.96, a P/E/G ratio of 1.63 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The stock has a 50 day moving average of $184.21 and a two-hundred day moving average of $213.79. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The company's revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.17 earnings per share. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.39%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.
Analyst Ratings Changes
A number of analysts have issued reports on the stock. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a research note on Friday, May 2nd. Morgan Stanley cut their target price on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their target price for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Finally, William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $219.22.
Check Out Our Latest Report on Becton, Dickinson and Company
Insider Activity
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the company's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares of the company's stock, valued at $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard Byrd sold 459 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the sale, the executive vice president now owns 6,952 shares in the company, valued at $1,598,960. This trade represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,104 shares of company stock valued at $399,675. 0.36% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the last quarter. Empowered Funds LLC boosted its stake in Becton, Dickinson and Company by 12.9% in the 4th quarter. Empowered Funds LLC now owns 6,623 shares of the medical instruments supplier's stock worth $1,503,000 after buying an additional 756 shares during the last quarter. Savant Capital LLC boosted its stake in Becton, Dickinson and Company by 85.9% in the 4th quarter. Savant Capital LLC now owns 14,628 shares of the medical instruments supplier's stock worth $3,319,000 after buying an additional 6,759 shares during the last quarter. Essex Financial Services Inc. boosted its stake in Becton, Dickinson and Company by 25.3% in the 4th quarter. Essex Financial Services Inc. now owns 2,662 shares of the medical instruments supplier's stock worth $604,000 after buying an additional 538 shares during the last quarter. Finally, Portfolio Design Labs LLC boosted its stake in Becton, Dickinson and Company by 59.4% in the 4th quarter. Portfolio Design Labs LLC now owns 1,640 shares of the medical instruments supplier's stock worth $372,000 after buying an additional 611 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.
Becton, Dickinson and Company Company Profile
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
